Article Sidebar

Download
PDF (Français)

Main Article Content

Abstract

RÉSUMÉ
Introduction. Notre étude avait pour but de comparer l’efficacité et la tolérance de l’ivermectine et du benzoate de benzyle dans la prise en charge de la gale humaine (GH) en milieu carcéral camerounais. Matériel et méthodes. Il s’agit d’un essai randomisé de comparabilité mené de Janvier à Juin 2015 à la prison principale de Mbouda. Nous avons inclus tout détenu présentant une GH et ayant consenti librement à participer. Tous les participants ont bénéficié d’une goutte épaisse calibrée (GEC) et ont été répartis en deux groupes. Le groupe I était traité par l’ivermectine orale et le groupe II avec le benzoate de benzyle. Une évaluation des deux groupes a été effectuée à deux, trois et quatre semaines après le traitement. Les données ont été analysées à l’aide du logiciel SPAD 5.5. Résultats. Au total, 257 détenus âgés de 14 à 77 ans avec un âge moyen de 32,1 ± 13 ans ont été examinés. Un participant avait une GEC positive et a été traité avec le benzoate de benzyle. Trente-neuf détenus ont été inclus dans le groupe I et 40 dans le groupe II. Après quatre semaines, 97,5% des participants étaient guéris dans le groupe II contre 94,9% dans le groupe I. Le benzoate de benzyle s’est avéré plus efficace que l’ivermectine. Par contre, l’ivermectine a été mieux tolérée. Cependant la différence n’était statistiquement significative (p>0,05). Conclusion.  Le benzoate de benzyle et l’ivermectine sont deux scabicides très efficaces dans la prise en charge de la GH.
ABSTRACT
Background: The aim of this study was to compare the efficacy and tolerance of ivermectin and benzyl benzoate in the treatment of human scabies (HS) in Cameroonian prisons. Material and method: This was a randomized comparability trial conducted from January to June 2015 at the main prison of Mbouda. We included any prisoner with HS who freely consented to participate. All participants received a calibrated thick drop (CTD) and were divided into two groups. Group I was treated with oral ivermectin and group II with benzyl benzoate. An evaluation of both groups was performed at two, three and four weeks post-treatment. The data were analysed using SPAD 5.5 software. Results: A total of 257 inmates aged 14 to 77 years with a mean age of 32.1 ± 13 years were examined. One participant had a positive CTD and was treated with benzyl benzoate. Thirty-nine inmates were included in Group I and 40 in Group II. After four weeks, 97.5% of the participants were cured in Group II compared to 94.9% in Group I. Benzyl benzoate was more effective than ivermectin. However, ivermectin was better tolerated. However, the difference was not statistically significant (p>0.05). Conclusion: Benzyl benzoate and ivermectin are two very effective scabicides in the management of HS. 

Article Details

Author Biography

Emmanuel Armand Kouotou, FMBS

Medical Imaging
How to Cite
Kouotou, E. A., Domche Medombou, C., Defo, D., Mendouga Menye, C. R., & Moyou Somo, R. (2020). Comparaison du Traitement de la Gale Humaine par l’Ivermectine et le Benzoate de Benzyle en Milieu Carcéral. HEALTH SCIENCES AND DISEASE, 21(8). https://doi.org/10.5281/hsd.v21i8.2212
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Chosidow O. Scabies and pediculosis. Lancet. 2000 Mar 4;355(9206):819–26.
  2. Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J. 2005;81(951):7–11.
  3. Hengge UR, Currie BJ, Jäger G, Lupi O, Schwartz RA. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis. 2006 Dec;6(12):769–79.
  4. Agrawal S, Puthia A, Kotwal A, Tilak R, Kunte R, Kushwaha AS. Mass scabies management in an orphanage of rural community: An experience. Med J Armed Forces India. 2012;68(4):403–6.
  5. Kouotou EA, Nansseu N.JR, Kouawa KM, Zoung-Kanyi Bissek AC. Prevalence and drivers of human scabies among children and adolescents living and studying in Cameroonian boarding schools. Parasites & Vectors (2016) 9:400. DOI 10.1186/s13071-016-1690-3
  6. Kouotou EA, Sieleunou I, Defo D, Nansseu NJR, Atenkeng Apasew H, Zoung-Kanyi Bissek A-C. Skin diseases among sub-saharian prisonners: the Cameroonian profile. Int J Clin Dermatol Res. 2014;2(701).
  7. Kouotou EA, Nansseu JRN, Sangare A, Moguieu Bogne L-L, Sieleunou I, Adegbidi H, Tameyi Tatsa J, Moyou Somo R. Burden of human scabies in sub-Saharan African prisons: Evidence from the west region of Cameroon. Australasian Journal of Dermatology (2018) 59, e6-e10. doi :10.1111/ajd.12540
  8. Bitar D, Caumes E, Chandre F, Del Guidice P, Gehanno J-F, Le Goaster C, et al.. Conduite à tenir devant un ou plusieurs cas de gale. Archives de Pédiatrie. 2013;(20):1358–63.
  9. McCarthy JS, Kemp DJ, Walton SF, Currie BJ. Scabies: more than just an irritation. Postgrad Med J. 2004;80(945):382–7.
  10. Goldust M, Rezaee E. The efficacy of topical ivermectin versus malation 0.5% lotion for the treatment of scabies. J Dermatol Treat. 2013;1–4.
  11. Goldust M, Rezaee E, Hemayat S. Treatment of scabies: Comparison of permethrin 5% versus ivermectin. J Dermatol. 2012;39(6):545–7.
  12. Goldust M, Rezaee E, Raghifar R. Comparison of oral ivermectin versus crotamiton 10% cream in the treatment of scabies. Cutan Ocul Toxicol. 2014;33(4):333–6.
  13. Nzenze JR, Kombila MY, Boguikouma JB, Belembaogo E, Moussavou-Kombila JB, Nguemby-Mbina C. Encéphalopathie mortelle au cours d’une loase hypermicrofilaremique traitée par ivermectine: Première description au Gabon. Médecine Afr Noire. 2001;48(8-9):375–7.
  14. Kamgno J, Boussinesq M. Hyperendémicité de la loase dans la plaine Tikar, région de savane arbustive du Cameroun. Santé publique (2001): 342-6
  15. Mogoung-Wafo AE, Nana-Djeunga HC, Domche A, Fossuo-Thotchum F, Bopda J, Mbickmen-Tchana S, Djomo-Kamga H, Kamgno J. Prevalence and intensity of Loa loa infection over twenty-three years in three communities of the Mbalmayo health district (Central Cameroon). BMC Infect Dis. 2019 Feb 13;19(1):146. doi: 10.1186/s12879-019-3776-y.
  16. Kelly-Hope LA, Hemingway J, Taylor MJ, Molyneux DH. Increasing evidence of low lymphatic filariasis prevalence in high risk Loa loa areas in Central and West Africa: a literature review. Parasit Vectors. 2018 Jun 15;11(1):349. doi: 10.1186/s13071-018-2900-y.
  17. Kouotou EA, Sieleunou I, Defo D, Nansseu NJR, Atenkeng Apasew H, Moyou Somo R, Zoung-Kanyi Bissek AC. Skin diseases among sub-Saharan African prisoners: the Cameroonian profile. IJCDR. 2014;2:701.
  18. Fujimoto K, Kawasaki Y, Morimoto K, Kikuchi I, Kawana S. Treatment for Crusted Scabies: Limitations and Side Effects of Treatment with Ivermectin. J Nippon Med Sch. 2014;81(3):157–63.
  19. Leppard B, Naburi AE. The use of ivermectin in controlling an outbreak of scabies in a prison. Br J Dermatol. 2000 Sep 1;143(3):520–3.
  20. Ly F, Caumes E, Ndaw CAT, Ndiaye B, Mahé A. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Organ. 2009 Jun;87(6):424–30.
  21. Hengge UR, Currie BJ, Jäger G, Lupi O, Schwartz RA. Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis. 2006;6(12):769–79.
  22. Meinking TL, Taplin D, Herminda JL, Pardo R, Kerdel FA. The Treatment of Scabies with Ivermectin. N Engl J Med. 1995 Jul 6;333(1):26–30.
  23. Haar K, Romani L, Filimone R, Kishore K, Tuicakou M, Koroivueta J, et al. Scabies community prevalence and mass drug administration in two Fijian villages. International Journal of Dermatology 53 (6), 2014: S. 739-45.
  24. Victor Leung, Mark Miller. Detection of scabies: A systematic review of diagnostic methods. Can J Infect Dis Med Microbiol. 2011 Winter; 22(4): 143–6.
  25. Mahe A, Faye O, N’Diaye HT. Definition of an algorithm for the management of common skin diseases at primary health care level in sub-Saharan Africa. Trans R Soc Trop Med Hyg. 2005;99:39–47.

Most read articles by the same author(s)

1 2 > >>